According to the study, the SGLT2 inhibitor empagliflozin can alleviate podocyte injury by reducing mTORC1 activity, enhancing autophagy, and attenuating inflammation in lupus-prone MRL/lpr mice (Table 4). This evidence concerns the gene SLC5A2 and systemic lupus erythematosus.